60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Saturday morning,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Tuesday, February 25th.

60 Degrees Pharmaceuticals Trading Up 5.1 %

NASDAQ:SXTP opened at $1.86 on Friday. The firm’s fifty day simple moving average is $2.81 and its 200 day simple moving average is $4.74. 60 Degrees Pharmaceuticals has a twelve month low of $1.41 and a twelve month high of $35.99. The firm has a market capitalization of $2.74 million, a price-to-earnings ratio of -0.18 and a beta of 4.52.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.